Fighting glaucoma with neuroprotective agents

Article

A pharmacoeconomic argument for neuroprotective agents is discussed

Glaucoma is a chronic, degenerative optic neuropathy characterized by the progressive thinning of the neuroretinal rim of the optic nerve, resulting in the enlargement of the opticnerve cup. Its cause is the loss of retinal ganglion cell axons, along with supporting glia and vasculature.

Glaucoma has been nicknamed the 'silent thief of sight' because the loss of vision normally occurs gradually over a long period of time and is often only recognized when the disease is quite advanced. Once lost, this damaged visual field cannot be recovered. Worldwide, it is the second leading cause of blindness affecting 1 in 200 people aged 50 and younger, and 1 in 10 over the age of 80.

Myogane* is a neuroprotectant that has been demonstrated to prevent retinal ganglion cell death in culture - a model of glaucoma in vitro and is currently in development by Phytopharm plc as a potential treatment for glaucoma. In glaucoma, the ganglion-cell axons that make up the optic nerve are damaged by a variety of factors, only some of which are understood.

The most important risk factor for glaucoma is elevated intraocular pressure (IOP) which is believed to provoke the neurodegeneration in susceptible subjects. However, even though elevated IOP is a significant risk factor, the majority of patients diagnosed with glaucoma have an IOP in the normal range.

The opticnerve damage in glaucoma is not yet amenable to direct treatment, consequently intervention is currently focused on the only known risk factor that can be modified, elevated IOP. Reduction in this is associated with a significant reduction in the rate of progression with the benefits of treatment being observed after 6 months of treatment.

However, glaucoma is a chronic condition and more than half of patients will demonstrate disease progression within 8–10 years of diagnosis despite efforts to reduce IOP. Poor compliance with medications is a major reason for vision loss in glaucoma patients.

A 2003 study found that half of patients in a health maintenance organization never filled their initial prescription for eye drops and another survey found that one in four patients failed to refill their prescriptions a second time, even though eye drops need to be used every day to be effective. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.

For these reasons, there is considerable interest in the development of oral drugs that may provide neuroprotection and thereby reduce the rate of glaucoma progression.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.